### Contents

**Highlights of This Issue** 5215

**SPECIAL FEATURES**

**CCR Translations**

5217  Overcoming Antiangiogenic Resistance
James C. Yao and Alexandria Phan
See article p. 5299

**CCR Perspectives in Drug Approval**

5220  The European Medicines Agency: An Overview of Its Mission, Responsibilities, and Recent Initiatives in Cancer Drug Regulation
Francesco Pignatti, Iordanis Gravanis, Ralf Herold, Spiros Vamvakas, Bertil Jonsson, and Michel Marty

**Molecular Pathways**

5226  Angiopoietin-2 TIEs Up Macrophages in Tumor Angiogenesis
Michele De Palma and Luigi Naldini

5233  Prostate Cancer Immunotherapy
Kenneth F. May, Jr., James L. Gulley, Charles G. Drake, Glenn Dranoff, and Philip W. Kantoff

**Special Report**

5239  SWOG Cooperative Group Biorepository Resource: Access for Scientific Research Studies
Carolyn J. Hoban, Wilbur A. Franklin, Kenneth J. Kopecky, and Laurence H. Baker

**Review**

5247  Prognostic Immune Markers in Non–Small Cell Lung Cancer
Kei Suzuki, Stefan S. Kachala, Kyuichi Kadota, Ronglai Shen, Qianxing Mo, David G. Beer, Valerie W. Rusch, William D. Travis, and Prasad S. Adusumilli

### HUMAN CANCER BIOLOGY

5257  Novel Functional Germline Variants in the VEGF Receptor 2 Gene and Their Effect on Gene Expression and Microvessel Density in Lung Cancer

5268  Clonal Relationship of Classical Hodgkin Lymphoma and its Recurrences
Ellen C. Oberrmann, Nadine Mueller, Alexander Ruffle, Thomas Menter, Esther Mueller-Garamvoelgyi, Gieri Cathomas, Stephan Dörnhofe, and Alexandar Tzankov

5275  FGFR Signaling Promotes the Growth of Triple-Negative and Basal-Like Breast Cancer Cell Lines Both In Vitro and In Vivo
Rachel Sharpe, Alex Pearson, Maria T. Herrera-Abreu, Damian Johnson, Alan Mackay, Jonathan C. Wilti, Rachael Natrajan, Andrew R. Reynolds, Jorge S. Reis-Filho, Alan Ashworth, and Nicholas C. Turner

5287  Regulatory Role of mir-203 in Prostate Cancer Progression and Metastasis
Sharanjot Saini, Shahana Majid, Soichiro Yamamura, Laura Tabatabai, Seong O. Suh, Varahram Shahrzad, Yi Chen, Guoren Deng, Yuichiro Tanaka, and Rajvir Dahiya

### CANCER THERAPY: PRECLINICAL

5299  Brivanib, a Dual FGF/VEGF Inhibitor, Is Active Both First and Second Line against Mouse Pancreatic Neuroendocrine Tumors Developing Adaptive/Evasive Resistance to VEGF Inhibition
Elizabeth Allen, Ian B. Walters, and Douglas Hanahan
See commentary p. 5217
**BARD1 Expression Predicts Outcome in Colon Cancer**
Judith C. Sporn, Torsten Hothorn, and Barbara Jung

**Gene Expression Profiling of Fixed Tissues Identified Hypoxia-Inducible Factor-1α, VEGF, and Matrix Metalloproteinase-2 as Biomarkers of Lymph Node Metastasis in Hepatocellular Carcinoma**
Zuo-Lin Xiang, Zhao-Chong Zeng, Jia Fan, Zhao-You Tang, Hai-Ying Zeng, and Dong-Mei Gao

**Immunosuppression in Patients with High-Grade Gliomas Treated with Radiation and Temozolomide**
Stuart A. Grossman, Xiaobu Ye, Glenn Lesser, Andrew Sloan, Hetty Carraway, Serena Desideri, and Steven Plantadosi for the NABTT CNS Consortium

**A Phase II Study of Pazopanib in Asian Patients with Recurrent/Metastatic Nasopharyngeal Carcinoma**
Wan-Teck Lim, Quan-Sing Ng, Percy Ivy, Swan-Swan Leong, Onkar Singh, Balram Chowbay, Fei Gao, Choon Hua Thng, Boon-Cher Goh, Daniel Shao-Weng Tan, Tong San Koh, Chee-Keong Toh, and Eng-Huat Tan

**Platinum Sensitivity-Related Germline Polymorphism Discovered via a Cell-Based Approach and Analysis of Its Association with Outcome in Ovarian Cancer Patients**

**Membranous Expression of Ectodomain Isoforms of the Epidermal Growth Factor Receptor Predicts Outcome after Chemoradiotherapy of Lymph Node–Negative Cervical Cancer**
Cathinka Halle, Malin Lando, Debbie Hege Svendsrud, Trevor Clancy, Marit Holden, Kolbein Sundlor, Gunnar B. Kristensen, Ruth Holm, and Heidi Lyng

**XPF Expression Correlates with Clinical Outcome in Squamous Cell Carcinoma of the Head and Neck**

**Correction: Regulation of HMGA1 Expression by MicroRNA-296 Affects Prostate Cancer Growth and Invasion**

**Correction: Intracellular Activation of SGN-35, a Potent Anti-CD30 Antibody-Drug Conjugate**
ABOUT THE COVER

Immunohistochemical analysis confirmed that YM155 reduced survivin protein levels, whereas docetaxel treatment increased p34 Thr-survivin protein at G2/M mitotic arrest. Furthermore, the concomitant treatment YM155 apparently decreased the docetaxel-induced survivin upregulation below the basal level in SK-MEL-5 human malignant melanoma cell. For further details, please see Yamanaka and colleagues on page 5423 in this issue.